Additional Proxy Soliciting Materials (definitive) (defa14a)
27 Septembre 2017 - 11:23PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section
14(a) of the Securities
Exchange Act of 1934
Filed by the Registrant
x
Filed by a Party other than the
Registrant
¨
Check the appropriate box:
|
¨
|
Preliminary Proxy Statement
|
|
¨
|
Confidential, for Use of the Commission Only (as permitted
by Rule 14a-6(e)(2))
|
|
o
|
Definitive Proxy Statement
|
|
x
|
Definitive Additional Materials
|
|
¨
|
Soliciting Material Pursuant to Rule 14a-12
|
ACURA PHARMACEUTICALS, INC.
(Name of Registrant as Specified In Its
Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check the appropriate
box):
|
¨
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4)
and 0-11.
|
|
(1)
|
Title of each class of securities to which transaction
applies:
|
|
(2)
|
Aggregate number of securities to which transaction
applies:
|
|
(3)
|
Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it
was determined):
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
¨
|
Fee paid previously with preliminary materials.
|
|
¨
|
Check box if any part of the fee is offset as provided
by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
(1)
|
Amount Previously Paid:
|
|
(2)
|
Form, Schedule or Registration Statement no.:
|
ACURA PHARMACEUTICALS,
INC. *** Exercise Your
Right
to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder
Meeting to Be Held on November 8, 2017.
BROADRIDGE CORPORATE ISSUER SOLUTIONS C/O ACURA PHARMACEUTICALS, INC. P.O. BOX
1342 BRENTWOOD, NY 11717
See the reverse side of this notice to obtain proxy materials and voting instructions.
E33082-P97520
You are receiving this communication because you hold shares in the company named above. This is not a ballot. You cannot use
this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available
to you on the Internet. You may view the proxy materials online at
www.proxyvote.com
or easily request a paper copy (see
reverse side). We encourage you to access and review all of the important information contained in the proxy materials before
voting.
Meeting Information Meeting Type:
Annual Meeting
For holders as of:
September 12, 2017
Date:
November
8, 2017
Time:
9:00 A.M. Eastern Time
Location:
LeClairRyan 1037 Raymond Blvd 16th Floor Newark, New Jersey 07102
Before
You Vote
How to Access the Proxy Materials
How To Vote
Please Choose One of the Following Voting Methods
Vote In
Person:
Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance
ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance.
At the meeting, you will need to request a ballot to vote these shares.
Vote By Internet:
To vote now by Internet, go to
www.proxyvote.com.
Have the information that is printed in the box marked by the arrow (located on the following page)
available and follow the instructions.
Vote By Mail:
You can vote by mail by requesting a paper copy of the materials,
which will include a proxy card. Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded
to your investment advisor. Please make the request as instructed above on or before October 25, 2017 to facilitate timely delivery.
How to View Online:
Have the information that is printed in the box marked by the arrow (located on the following page)
and visit:
www.proxyvote.com.
How to Request and Receive a PAPER or E-MAIL Copy:
If you want to receive a paper
or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following
methods to make your request: 1)
BY INTERNET
: www.proxyvote.com 2)
BY TELEPHONE
: 1-800-579-1639 3)
BY E-MAIL*
:
sendmaterial@proxyvote.com * If requesting materials by e-mail, please send a blank e-mail with the information that is printed
in the box marked by the arrow (located on the following page) in the subject line. NOTICE AND PROXY STATEMENT FORM 10-K
Proxy
Materials Available to VIEW or RECEIVE:
Voting Items
3. Non-binding advisory vote on the frequency of the shareholder vote on executive compensation. 4. Approval of the Acura
Pharmaceuticals, Inc. 2017 Restricted Stock Unit Award Plan. 2. Non-binding advisory vote to approve executive compensation. 1.
Election of Directors 01) Immanuel Thangaraj 02) Bruce F. Wesson 03) Robert B. Jones 04) William G. Skelly 05) George K. Ross
Nominees: The Board of Directors recommends you vote FOR the following: The Board of Directors recommends you vote FOR the
following proposal: The Board of Directors recommends you vote FOR the following proposals: The Board of Directors recommends
you vote 3 YEARS on the following proposal:
5. Ratification of the appointment of BDO USA, LLP as our independent registered
public accounting firm for the fiscal year ending December 31, 2017.
NOTE:
IN THEIR DISCRETION PROXIES ARE AUTHORIZED TO
VOTE AS SAID PROXIES DEEM ADVISABLE ON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING AND ANY POSTPONEMENT OR ADJOURNMENT
THEREOF.
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024